WO2003080800A3 - Prevention and treatment of disease using angiogenesis-and/or tumor antigens - Google Patents

Prevention and treatment of disease using angiogenesis-and/or tumor antigens Download PDF

Info

Publication number
WO2003080800A3
WO2003080800A3 PCT/US2003/008536 US0308536W WO03080800A3 WO 2003080800 A3 WO2003080800 A3 WO 2003080800A3 US 0308536 W US0308536 W US 0308536W WO 03080800 A3 WO03080800 A3 WO 03080800A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
treatment
angiogenesis
disease
tumor antigens
Prior art date
Application number
PCT/US2003/008536
Other languages
French (fr)
Other versions
WO2003080800A2 (en
Inventor
Neil Berinstein
Corey Lovitt
Mark Parrington
Artur Pedyczak
Laszlo Radvanyi
Devender Singh-Sandhu
Original Assignee
Aventis Pasteur Inc
Neil Berinstein
Corey Lovitt
Mark Parrington
Artur Pedyczak
Laszlo Radvanyi
Devender Singh-Sandhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur Inc, Neil Berinstein, Corey Lovitt, Mark Parrington, Artur Pedyczak, Laszlo Radvanyi, Devender Singh-Sandhu filed Critical Aventis Pasteur Inc
Priority to AU2003228339A priority Critical patent/AU2003228339A1/en
Publication of WO2003080800A2 publication Critical patent/WO2003080800A2/en
Publication of WO2003080800A3 publication Critical patent/WO2003080800A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the use of nucleic acids, polypeptides, and/or derivatives thereof for preventing and/or treating diseases. In particular, the invention relates to the prevention and/or treatment of cancer.
PCT/US2003/008536 2002-03-20 2003-03-20 Prevention and treatment of disease using angiogenesis-and/or tumor antigens WO2003080800A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003228339A AU2003228339A1 (en) 2002-03-20 2003-03-20 Prevention and treatment of disease using angiogenesis-and/or tumor antigens

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36598202P 2002-03-20 2002-03-20
US60/365,982 2002-03-20

Publications (2)

Publication Number Publication Date
WO2003080800A2 WO2003080800A2 (en) 2003-10-02
WO2003080800A3 true WO2003080800A3 (en) 2004-01-15

Family

ID=28454736

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/008536 WO2003080800A2 (en) 2002-03-20 2003-03-20 Prevention and treatment of disease using angiogenesis-and/or tumor antigens

Country Status (2)

Country Link
AU (1) AU2003228339A1 (en)
WO (1) WO2003080800A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2408328C (en) 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
AU2003223527B2 (en) 2002-04-09 2009-01-15 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
BRPI0413334A (en) * 2003-09-05 2006-10-10 Sanofi Pasteur Ltd multigene vectors for melanoma
KR101162970B1 (en) 2003-10-08 2012-07-12 테리온 바이오로직스, 인크. Modified CEA/B7 vector
WO2005068640A2 (en) * 2003-12-23 2005-07-28 Aventis Pasteur, Inc. Modified ksa and uses thereof
US20100028256A1 (en) 2006-11-09 2010-02-04 St Croix Brad Differential gene expression in physiological and pathological angiogenesis
WO2008101118A2 (en) 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030073613A1 (en) * 2000-03-22 2003-04-17 Mary Gerritsen Angiogenisis associated proteins, and nucleic acids encoding the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030073613A1 (en) * 2000-03-22 2003-04-17 Mary Gerritsen Angiogenisis associated proteins, and nucleic acids encoding the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OKABE S. ET AL.: "BAZF, a novel Bc16 homolog, functions as a transcriptional repressor", MOL. CELL. BIOL., vol. 18, no. 7, July 1998 (1998-07-01), pages 4235 - 4244, XP002237973 *
SAKASHITA C. ET AL.: "Cloning and characterization of the human BAZF gene, a homologue of the BCL6 oncogene", BIOCHEM. BIOPHYS. RES. COMM., vol. 291, 1 March 2002 (2002-03-01), pages 567 - 573, XP002971996 *

Also Published As

Publication number Publication date
WO2003080800A2 (en) 2003-10-02
AU2003228339A1 (en) 2003-10-08
AU2003228339A8 (en) 2003-10-08

Similar Documents

Publication Publication Date Title
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2003080582A3 (en) Fredericamycin derivatives
WO2004050707A3 (en) Tumor-specific recognition molecules
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
WO2004065423A3 (en) Recognition molecules for the treatment and detection of tumours
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
HK1080840A1 (en) Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
ZA200500882B (en) Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis of treatment or liver disorders and epithelial cancer
WO2004071382A3 (en) Substituted heterocycles
HK1078585A1 (en) Water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases
HK1079220A1 (en) Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases cd83
WO1998059040A3 (en) Human catalytic telomerase sub-unit and its diagnostic and therapeutic use
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
WO2004104039A8 (en) Tumor antigens for prevention and/or treatment of cancer
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
AU2002313426A1 (en) Tumor antigens for prevention and/or treatment of cancer
WO2004005540A3 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
WO2002066492A3 (en) Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof
WO2000043028A3 (en) Method of treating chronic cardiac disease
WO2005023288A8 (en) Treatment of fibrotic disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP